Elekta AB (EKTAY)
OTHER OTC:EKTAY
EKTAY Stock Chart & Stats
$6.37
-$0.10(-1.78%)
At close: 4:00 PM EST
$6.37
-$0.10(-1.78%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume122.00
Average Volume (3M)73.00
Market Cap
$2.21B
Enterprise Value$24.44B
Total Cash (Recent Filing)$2.56B
Total Debt (Recent Filing)$7.34B
Price to Earnings (P/E)567.4
Beta1.30
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.21%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume73
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)2.12
Price to Sales (P/S)1.04
P/FCF Ratio17.69
Enterprise Value/Market Cap11.08
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit3.84
Enterprise Value/Ebitda12.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent operating and free cash flow provide durable internal funding for R&D, service execution and working-capital needs in a capital-intensive business. Strong cash conversion cushions cyclical equipment sales swings and supports debt repayment and strategic investments over months to years.
US FDA Approval And Product LaunchesRegulatory approval and new product rollouts expand the addressable market and build a multi-year product funnel. FDA clearance eases US commercialization, strengthens upgrade/replacement demand and supports recurring service and software revenues tied to deployed systems.
China Recovery And Market LeadershipRebound in China with high market share provides durable growth levers and diversification versus mature markets. Leadership in new placements secures an expanding installed base that supports long-term service, upgrade and software revenue streams as hospitals modernize.
Bears Say
Profitability DeteriorationContinuing margin compression and a transition to a TTM net loss signal weaker operating leverage and reduced earnings quality. Persistently lower profitability limits reinvestment capacity, weakens returns on equity and raises dependence on cash flow to fund growth and debt servicing.
Rising LeverageAn elevated and rising debt-to-equity ratio constrains financial flexibility for funding large capital projects or strategic launches. Higher leverage increases interest and refinancing risk, reducing resilience to sales volatility in a cyclical, tender-driven equipment market.
Material FX And Tariff HeadwindsSignificant and persistent currency and tariff exposure can structurally erode reported sales and margins in international equipment sales. These external pressures complicate long-term pricing, procurement by hospitals, and margin planning in markets where pricing power is limited.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $2.21B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Jun 03, 2026 which is in 54 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Mar 05, 2026. The company reported $0.003 earnings per share for the quarter, beating the consensus estimate of N/A by $0.003.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.064 which represents an annual dividend yield of 0.21%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of $0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.228%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.41%
12-Months-Change
Fundamentals
Return on Equity
-0.45%
Trailing 12-Months
Asset Growth
4.93%
Trailing 12-Months
Company Description
Elekta AB
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
EKTAY Company Deck
EKTAY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: clear commercial and operational positives (product approvals and launches, China recovery, improved gross margin and strong cash EBIT momentum, healthy book-to-bill and YTD cash flow improvement) alongside meaningful near-term headwinds (large FX and tariff impacts, a SEK 417m restructuring charge with further P&L effects, Americas revenue decline and some regional slowdowns). Management reiterated guidance, outlined structural cost savings (>SEK 500m run-rate) and emphasized execution of a new operating model. Given the mix of encouraging execution/operational improvements and significant external and one-time pressures, the tone is constructive but cautious.View all EKTAY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---